Did the company provide guidance for the remainder of FY2026, and how does it compare to analysts' forecasts?

Guidance: In the PetVivo Q1 2026 release the company only disclosed the quarter’s operating and financial results. There was no forward‑looking statement or revenue/earnings guidance for the balance of fiscal‑year 2026 (the period ending June 30 2026).

Analyst expectations: Because PetVivo did not issue its own FY 2026 outlook, market participants are still relying on the consensus forecasts compiled by sell‑side analysts. Those forecasts – which were already priced into the stock prior to the earnings call – therefore remain the primary benchmark for the rest of the year. In other words, the company’s lack of guidance leaves analysts’ estimates unchanged, and any deviation (up‑ or down‑beat) will have to be inferred from subsequent quarterly updates or a future guidance release.

Trading implication: With guidance absent, the stock’s near‑term price action will be driven more by the Q1 performance versus expectations and by broader sector dynamics (e.g., animal‑health device demand, macro‑risk appetite). If the quarter beat or missed consensus, the market may pre‑price a potential FY 2026 outlook in the next update. Until PetVivo issues its own FY 2026 guidance, traders should monitor analyst revisions and the company’s Q2 results for the first concrete signal of the remainder‑of‑year trajectory. A short‑to‑neutral stance is prudent until clearer forward‑looking guidance emerges.